These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
655 related articles for article (PubMed ID: 33479118)
1. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Bubar KM; Reinholt K; Kissler SM; Lipsitch M; Cobey S; Grad YH; Larremore DB Science; 2021 Feb; 371(6532):916-921. PubMed ID: 33479118 [TBL] [Abstract][Full Text] [Related]
2. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Bubar KM; Reinholt K; Kissler SM; Lipsitch M; Cobey S; Grad YH; Larremore DB medRxiv; 2021 Jan; ():. PubMed ID: 33330882 [TBL] [Abstract][Full Text] [Related]
3. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185 [TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836 [TBL] [Abstract][Full Text] [Related]
5. Differential COVID-19 case ascertainment by age and vaccination status in Victoria, Australia: a serosurveillance and record linkage study. Szanyi J; Price DJ; Carville KS; Batty M; Yallop S; Nicholson S; Karapanagiotidis T; Rowe S; Sullivan S; Menon V; West D; Manoharan L; Copsey E; Majumdar SS; Sutton B; Williamson DA; McVernon J Commun Dis Intell (2018); 2024 Aug; 48():. PubMed ID: 39165016 [TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362 [TBL] [Abstract][Full Text] [Related]
7. Time-varying optimization of COVID-19 vaccine prioritization in the context of limited vaccination capacity. Han S; Cai J; Yang J; Zhang J; Wu Q; Zheng W; Shi H; Ajelli M; Zhou XH; Yu H Nat Commun; 2021 Aug; 12(1):4673. PubMed ID: 34344871 [TBL] [Abstract][Full Text] [Related]
8. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675 [TBL] [Abstract][Full Text] [Related]
9. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia. McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236 [TBL] [Abstract][Full Text] [Related]
10. The impact of quality-adjusted life years on evaluating COVID-19 mitigation strategies: lessons from age-specific vaccination roll-out and variants of concern in Belgium (2020-2022). Willem L; Abrams S; Franco N; Coletti P; Libin PJK; Wambua J; Couvreur S; André E; Wenseleers T; Mao Z; Torneri A; Faes C; Beutels P; Hens N BMC Public Health; 2024 Apr; 24(1):1171. PubMed ID: 38671366 [TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans. Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM Front Immunol; 2021; 12():728021. PubMed ID: 34646267 [TBL] [Abstract][Full Text] [Related]
14. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193 [TBL] [Abstract][Full Text] [Related]
15. The long road. Cohen J Science; 2021 Feb; 371(6531):768-772. PubMed ID: 33602838 [No Abstract] [Full Text] [Related]